Algorae Pharmaceuticals Limited
LVCLF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $125 | $42 | $3 |
| % Growth | -100% | 198% | 1,134% | – |
| Cost of Goods Sold | $0 | $0 | $1 | $1 |
| Gross Profit | $0 | $125 | $41 | $3 |
| % Margin | – | 100% | 98.7% | 78.2% |
| R&D Expenses | $855 | $739 | $1,310 | $1,463 |
| G&A Expenses | $176 | $201 | $212 | $0 |
| SG&A Expenses | $212 | $966 | $213 | $912 |
| Sales & Mktg Exp. | $36 | $765 | $1 | $0 |
| Other Operating Expenses | $489 | $498 | $606 | $1 |
| Operating Expenses | $1,555 | $2,203 | $2,129 | $2,377 |
| Operating Income | -$1,555 | -$2,078 | -$2,087 | -$2,385 |
| % Margin | – | -1,659.5% | -4,968.3% | -70,042.7% |
| Other Income/Exp. Net | $15 | -$18 | -$20 | $13 |
| Pre-Tax Income | -$1,540 | -$2,096 | -$2,108 | -$2,372 |
| Tax Expense | $737 | $0 | $0 | -$415 |
| Net Income | -$803 | -$2,096 | -$2,108 | -$1,957 |
| % Margin | – | -1,673.8% | -5,016.3% | -57,483.1% |
| EPS | -0.001 | -0.001 | -0.002 | -0.002 |
| % Growth | 61.5% | 18.8% | 27.3% | – |
| EPS Diluted | -0.001 | -0.001 | -0.002 | -0.002 |
| Weighted Avg Shares Out | 1,609,134 | 1,613,212 | 1,346,990 | 886,621 |
| Weighted Avg Shares Out Dil | 1,687,394 | 1,663,114 | 1,346,990 | 886,621 |
| Supplemental Information | – | – | – | – |
| Interest Income | $138 | $125 | $42 | $3 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,067 | $1 | $1 | $1 |
| EBITDA | $0 | -$1,579 | -$1,521 | -$1,459 |
| % Margin | – | -1,261.3% | -3,619.7% | -42,848.3% |